AZNCF: AI 评分 60/100 — AI 分析 (4月 2026)

AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. The company operates across various therapeutic areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology.

Key Facts: AI Score: 60/100 Sector: Healthcare

公司概况

概要：

AstraZeneca PLC is a global biopharmaceutical leader specializing in prescription medicines across oncology, cardiovascular, renal & metabolism, and respiratory & immunology. With a strong focus on innovation and strategic collaborations, AstraZeneca serves primary and specialty care physicians worldwide, maintaining a significant presence in key therapeutic areas.

AZNCF是做什么的？

AstraZeneca PLC, established in 1992 and headquartered in Cambridge, UK, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing prescription medicines. Formed through the merger of Astra AB and Zeneca Group PLC in 1999, AstraZeneca has evolved into a major player in the pharmaceutical industry. The company's diverse portfolio includes well-known products such as Calquence, Enhertu, and Lynparza in oncology; Brilinta and Farxiga in cardiovascular, renal, and metabolism; and Symbicort and Fasenra in respiratory and immunology. AstraZeneca also addresses rare diseases with products like Soliris and Ultomiris. The company operates globally, serving primary care and specialty care physicians through distributors and local representative offices across Europe, the Americas, Asia, Africa, and Australasia. AstraZeneca's commitment to innovation is underscored by its collaborations with companies like Regeneron Pharmaceuticals, Neurimmune AG, Ionis Pharmaceuticals, Proteros Biostructures GmbH, and Sierra Oncology, Inc., focusing on areas such as obesity, neurological disorders, and cancer treatments.

AZNCF的投资论点是什么？

AstraZeneca PLC presents a compelling investment case driven by its robust product portfolio and strategic focus on key therapeutic areas. With a market capitalization of $294.40 billion and a profit margin of 17.4%, the company demonstrates financial stability. Growth catalysts include ongoing collaborations and the development of novel therapies, particularly in oncology and rare diseases. The company's dividend yield of 1.64% provides a steady return for investors. However, potential risks include regulatory hurdles and competition from other pharmaceutical giants. The company's P/E ratio of 28.76 reflects investor expectations of future growth.

AZNCF在哪个行业运营？

AstraZeneca operates in the highly competitive global pharmaceutical industry, characterized by intense research and development, stringent regulatory requirements, and patent protection. The industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology. AstraZeneca competes with major pharmaceutical companies, including CHGCF (Chugai Pharmaceutical Co.), CHGCY (Chugai Pharmaceutical Co.), FSNUY (Fresenius SE & Co), NONOF (Novo Nordisk), and NVSEF (Novartis). The company's success depends on its ability to innovate, secure regulatory approvals, and effectively market its products.

Drug Manufacturers - General

Healthcare

AZNCF有哪些增长机遇？

Expansion in Oncology: AstraZeneca has a significant opportunity to expand its oncology portfolio, which includes key drugs like Lynparza and Tagrisso. The global oncology market is projected to reach $286.6 billion by 2030, driven by increasing cancer prevalence and advancements in targeted therapies. AstraZeneca's ongoing research and development efforts, coupled with strategic acquisitions, position it to capture a larger share of this growing market. The company's focus on precision medicine and immuno-oncology offers a competitive edge.
Cardiovascular, Renal & Metabolism (CVRM) Growth: AstraZeneca's CVRM franchise, featuring drugs like Farxiga, presents a substantial growth opportunity. The global market for cardiovascular drugs is expected to reach $165 billion by 2028, driven by the rising incidence of heart disease and diabetes. AstraZeneca's innovative therapies and focus on preventative care position it to capitalize on this trend. The company's commitment to addressing unmet needs in CVRM through novel drug development supports long-term growth.
Respiratory & Immunology Advancements: AstraZeneca's respiratory and immunology portfolio, including products like Symbicort and Fasenra, offers growth potential. The global respiratory disease market is projected to reach $47.7 billion by 2027, driven by increasing air pollution and the prevalence of asthma and COPD. AstraZeneca's focus on developing inhaled therapies and biologics for respiratory diseases provides a competitive advantage. The company's expansion into biologics for autoimmune diseases further enhances its growth prospects.
Rare Diseases Portfolio Expansion: AstraZeneca's acquisition of Alexion Pharmaceuticals has significantly expanded its presence in the rare diseases market. The global rare diseases market is expected to reach $258.74 billion by 2030, driven by increased awareness and advancements in genetic testing. AstraZeneca's portfolio, including Soliris and Ultomiris, positions it to address unmet needs in this growing market. The company's focus on developing innovative therapies for rare genetic disorders supports long-term growth.
Strategic Collaborations and Partnerships: AstraZeneca's collaborations with companies like Regeneron, Neurimmune, and Ionis Pharmaceuticals provide access to innovative technologies and drug candidates. These partnerships enable AstraZeneca to expand its pipeline and address unmet needs in various therapeutic areas. The company's collaborative approach to drug development accelerates innovation and enhances its competitive position. Ongoing collaborations are expected to contribute to long-term growth and diversification of its product portfolio.

Market Cap of $294.40B indicates a strong market presence and investor confidence.
Profit Margin of 17.4% demonstrates efficient operations and profitability.
Gross Margin of 78.2% reflects strong pricing power and cost management.
Dividend Yield of 1.64% provides a steady income stream for investors.
Beta of 0.19 suggests lower volatility compared to the overall market.

AZNCF提供哪些产品和服务？

Discovers and develops prescription medicines.
Manufactures pharmaceutical products.
Commercializes prescription medicines globally.
Focuses on therapeutic areas including oncology, cardiovascular, renal & metabolism, and respiratory & immunology.
Addresses rare diseases with specialized treatments.
Develops vaccines for infectious diseases like COVID-19 and influenza.
Engages in research and development collaborations with other companies.

AZNCF如何赚钱？

Develops and patents new pharmaceutical products.
Conducts clinical trials to demonstrate safety and efficacy.
Obtains regulatory approvals from agencies like the FDA and EMA.
Manufactures and distributes drugs through distributors and local offices.
Markets and sells prescription medicines to healthcare providers and patients.

Primary care physicians
Specialty care physicians
Hospitals and clinics
Patients with various medical conditions
Government healthcare organizations

Patent protection for key drugs provides exclusivity and pricing power.
Strong brand reputation and established relationships with healthcare providers.
Extensive research and development capabilities drive innovation.
Global distribution network ensures broad market access.
Specialized expertise in key therapeutic areas creates a competitive advantage.

什么因素可能推动AZNCF股价上涨？

Upcoming: Clinical trial results for key drug candidates in oncology and other therapeutic areas.
Upcoming: Regulatory approvals for new drugs and indications.
Ongoing: Strategic collaborations and partnerships to expand the product pipeline.
Ongoing: Expansion into emerging markets to drive revenue growth.
Ongoing: Continued focus on research and development to innovate new therapies.

AZNCF的主要风险是什么？

Potential: Patent expirations and loss of exclusivity for key drugs.
Potential: Increasing competition from generic drug manufacturers.
Potential: Pricing pressures and healthcare reforms.
Ongoing: Regulatory risks and challenges.
Ongoing: High research and development costs.

AZNCF的核心优势是什么？

Strong product portfolio in key therapeutic areas.
Robust research and development pipeline.
Global presence and distribution network.
Strategic collaborations and partnerships.

AZNCF的劣势是什么？

Reliance on patent protection for key drugs.
Exposure to generic competition.
Regulatory risks and challenges.
High research and development costs.

AZNCF有哪些机遇？

Expansion into emerging markets.
Development of novel therapies for unmet needs.
Strategic acquisitions and partnerships.
Growth in personalized medicine and targeted therapies.

AZNCF面临哪些威胁？

Increasing competition from generic drug manufacturers.
Pricing pressures and healthcare reforms.
Patent expirations and loss of exclusivity.
Adverse regulatory decisions.

AZNCF的竞争对手是谁？

Chugai Pharmaceutical Co. — Focuses on prescription pharmaceuticals and is based in Japan. — (CHGCF)
Chugai Pharmaceutical Co. — ADR of Chugai Pharmaceutical Co. — (CHGCY)
Fresenius SE & Co — Diversified healthcare company with a focus on dialysis and hospital services. — (FSNUY)
Novo Nordisk — Specializes in diabetes care and biopharmaceuticals. — (NONOF)
Novartis — Global pharmaceutical company with a broad range of products. — (NVSEF)

Key Metrics

MoonshotScore: 60/100

Company Profile

CEO: Pascal Claude Roland Soriot
Headquarters: Cambridge, GB
Employees: 94,300
Founded: 2009

AI Insight

AI analysis pending for AZNCF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does AstraZeneca PLC do?

AstraZeneca PLC is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. The company focuses on key therapeutic areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca's products are sold worldwide to primary care and specialty care physicians, hospitals, and government healthcare organizations. The company also engages in research and development collaborations to expand its product pipeline and address unmet medical needs.

What do analysts say about AZNCF stock?

Analyst consensus for AZNCF stock is generally positive, reflecting the company's strong product portfolio and growth prospects. Key valuation metrics, such as the P/E ratio of 28.76, suggest that investors expect future earnings growth. Considerations include the company's ongoing research and development efforts, strategic collaborations, and expansion into emerging markets. However, analysts also note potential risks, such as patent expirations and regulatory challenges. No buy/sell recommendations are made in this research report.

What are the main risks for AZNCF?

The main risks for AZNCF include patent expirations and loss of exclusivity for key drugs, increasing competition from generic drug manufacturers, pricing pressures and healthcare reforms, regulatory risks and challenges, and high research and development costs. These factors could negatively impact the company's revenue, profitability, and market share. Investors should carefully consider these risks before investing in AZNCF stock. The OTC market also presents additional risks.